AltaRex Completes Pivotal OvaRex Clinical Trial.(Brief Article)

2001 OCT 9 - (NewsRx.com & NewsRx.net) --

AltaRex Corp. (AXO.TO, ALXFF.OTC) has completed primary analysis of the company's designated pivotal 345-patient OvaRex trial and may be ready to submit Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) as early as year-end. Primary results from the trial will form the foundation of the company's application for marketing approval of OvaRex MAb.

With the patient treatment now complete for this lead trial, an Endpoint Monitoring Board (EMB) will independently assess time to disease relapse surrogate endpoints on individual patients' case record forms over the next two to three months. …